Altimunne (ALT)

Altimmune, Inc (ALT) CEO Bill Enright on Q2 2018 Results - Earnings Call Transcript
Aug. 15, 2018 | Price: Free! | Source: Seeking Alpha

PharmAthene's CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 12, 2014 | Price: Free! | Source: Seeking Alpha

PharmAthene Management Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc - Q2 2013 Earnings Call Transcript
Aug. 7, 2013 | Price: Free! | Source: Earnings Impact

PharmAthene, Inc. Q2 2013 Earnings Conference Call Transcript
Aug. 7, 2013 | Price: $106.00 | Source: Thomson

PharmAthene, Inc., Theraclone Sciences, Inc. - M&A Call
Aug. 1, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics
Aug. 1, 2013 | Price: $106.00 | Source: Thomson

PharmAthene Management Discusses Q1 2013 Results - Earnings Call Transcript
May 8, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. Q1 2013 Earnings Conference Call Transcript
May 8, 2013 | Price: $54.00 | Source: Thomson

PharmAthene, Inc. Q4 2012 Earnings Conference Call Transcript
March 13, 2013 | Price: $106.00 | Source: Thomson

PharmAthene Management Discusses Q4 2012 Results - Earnings Call Transcript
March 13, 2013 | Price: Free! | Source: Seeking Alpha

PharmAthene Management Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 6, 2012 | Price: Free! | Source: Seeking Alpha

PharmAthene, Inc. Q3 2012 Earnings Conference Call Transcript
Nov. 6, 2012 | Price: $54.00 | Source: Thomson

PharmAthene, Inc. Q1 2012 Earnings Conference Call Transcript
May 8, 2012 | Price: $54.00 | Source: Thomson

Recent filings

Departure of Directors or Certain - June 21, 2019

Altimunne's Chief Medical Officer was just granted 20,000 options - June 19, 2019

Altimunne: Altimmune Appoints Will Brown As Chief Financial Officer GAITHERSBURG, Maryland, June - June 12, 2019

Altimunne's Chief Financial Officer was just granted 50,000 options - June 12, 2019

Departure of Directors or Certain - June 7, 2019

Altimunne Just Filed Its Quarterly Report: 3.Net Loss Per Share... - May 14, 2019

Altimunne: Altimmune Announces First Quarter 2019 Financial Results And Provides A Business Update - May 14, 2019

Altimunne Just Received a Notice of Effectiveness - April 12, 2019

Registration statement under Securities Act of 1933 - April 4, 2019

Securities to be offered to employees in employee benefit plans - April 4, 2019

Altimunne: Altimmune Announces Financial Results For The Year Ended December 31, 2018 And Provides Corporate Update - April 1, 2019

Altimunne Just Filed Its Annual Report: 4. Net Loss Per... - April 1, 2019

Altimunne's Chief Scientific Officer was just granted 38,000 options - March 27, 2019

Altimunne's Chief Medical Officer was just granted 38,000 options - March 27, 2019

Departure of Directors or Certain - March 15, 2019

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - March 11, 2019

Altimunne: Altimmune Announces $14 Million Registered Direct Offering - March 11, 2019

Altimunne: Altimmune Announces Clinical Program Updates And Plans For Pipeline Expansion - March 8, 2019

OFCO Club V just provided an update on share ownership of Altimunne - Feb. 11, 2019

Intracoastal Capital LLC just provided an update on share ownership of Altimunne - Feb. 8, 2019

Novartis AG just provided an update on share ownership of Altimunne - Feb. 5, 2019

Sander Gerber just provided an update on share ownership of Altimunne - Feb. 1, 2019

Altimunne director was just granted 30,000 options - Jan. 4, 2019

Altimunne's Chief Medical Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's Chief Scientific Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne's Acting Chief Financial Officer was just granted 30,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne director was just granted 20,000 options - Jan. 4, 2019

Altimunne's President and CEO just declared ownership of no shares of Altimunne - Dec. 4, 2018

Departure of Directors or Certain - Dec. 3, 2018

Summary Consolidated Financial Data - Nov. 30, 2018

Departure of Directors or Certain - Oct. 22, 2018

Statement of acquisition of beneficial ownership by individuals - Oct. 17, 2018

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - Oct. 9, 2018

Heights Capital Management, Inc. just provided an update on share ownership of Altimunne - Oct. 5, 2018

Major owner of Altimunne just declared ownership of no shares of Altimunne - Oct. 4, 2018

Confidential treatment order - Oct. 4, 2018

Novartis AG just provided an update on share ownership of Altimunne - Oct. 4, 2018

Post-effective amendment adding exhibits to registration statement [Rule 462(d)] - Sept. 28, 2018

Altimunne Just Received a Notice of Effectiveness - Sept. 27, 2018

General form for registration of securities under the Securities Act of 1933 - Sept. 26, 2018

Altimunne: Altimmune Announces $4.9 Million Registered Direct Offering Of Common Stock GAITHERSBURG, MD, September - Sept. 25, 2018

Altimunne just filed a prospectus, suggesting it plans to soon issue some securities - Sept. 24, 2018

Altimunne: Altimmune Awarded $2.5 Million In Additional Barda Funding To Support - Sept. 24, 2018

Major owner of Altimunne just picked up 2,069,993 shares - Sept. 14, 2018

Amendments to Article of Incorporation or - Sept. 13, 2018

The Companys stockholders had previously approved a reverse split ratio of not less than - Sept. 12, 2018

Altimunne director just declared ownership of no shares of Altimunne - Sept. 10, 2018

Altimunne: Altimmune Announces Additional Positive Data From Its Phase 2A Study - Sept. 4, 2018

Altimunne: Altimmune Announces Initial Single-Dose Data From Its Nasoshield Phase 1 Study - Aug. 31, 2018

General form for registration of securities under the Securities Act of 1933 - Aug. 17, 2018

General form for registration of securities under the Securities Act of 1933 - July 30, 2018

PharmAthene: Altimmune Restructures Financing Agreement With Substantially All Of The Remaining Series B Investors - July 16, 2018

Other preliminary proxy statements - July 16, 2018

Major owner of PharmAthene just picked up 663,346 shares - July 13, 2018

PharmAthene: Altimmune Restructures Financing Agreement - June 25, 2018

Departure of Directors or Certain - June 22, 2018

Major owner of PharmAthene just picked up 14,449 shares - June 19, 2018

Major owner of PharmAthene just picked up 720,878 shares - June 15, 2018

PharmAthene's Acting Chief Financial Officer just declared ownership of no shares of PharmAthene - May 31, 2018

PharmAthene's President and CEO just picked up 1,300 shares - May 29, 2018

PharmAthene's President and CEO was just granted 103,158 options - May 23, 2018

PharmAthene's Chief Scientific Officer just picked up 55,120 shares - May 23, 2018

PharmAthene's Chief Medical Officer was just granted 50,016 options - May 23, 2018

Notice of Delisting or Failure to Satisfy a Continued Listing - May 18, 2018

Major owner of PharmAthene just picked up 1,042,431 shares - May 17, 2018

Departure of Directors or Certain - May 10, 2018

Major owner of PharmAthene just picked up 700,066 shares - April 18, 2018

PharmAthene director was just granted 35,000 options - April 6, 2018

PharmAthene Just Filed Its Annual Report: 5. Net Loss Per S... - April 2, 2018

PharmAthene: Altimmune Announces Financial Results For The Year Ended December 31, 2017 And Provides Corporate Update - March 29, 2018

Major owner of PharmAthene just picked up 261,969 shares - March 19, 2018

Major owner of PharmAthene just picked up 337,452 shares - Feb. 15, 2018

Major owner of PharmAthene just picked up 74,240 shares - Feb. 15, 2018

Renaissance Technologies LLC just provided an update on share ownership of PharmAthene - Feb. 14, 2018

OFCO Club V just provided an update on share ownership of PharmAthene - Feb. 12, 2018

Truffle Capital S.A.S. just provided an update on share ownership of PharmAthene - Feb. 9, 2018

Sander Gerber just provided an update on share ownership of PharmAthene - Feb. 2, 2018

Novartis AG just provided an update on share ownership of PharmAthene - Feb. 2, 2018

Major owner of PharmAthene just picked up 176,586 shares - Jan. 19, 2018

Major owner of PharmAthene just picked up 38,851 shares - Jan. 19, 2018

PharmAthene's President and CEO just picked up 183,347 shares - Jan. 4, 2018

PharmAthene director just picked up 97,410 shares - Jan. 2, 2018

PharmAthene director just picked up 147,130 shares - Dec. 27, 2017

Major owner of PharmAthene just picked up 308,412 shares - Dec. 15, 2017

Major owner of PharmAthene just picked up 67,851 shares - Dec. 15, 2017

PharmAthene director just picked up 23,745 shares - Dec. 8, 2017

PharmAthene director just picked up 26,010 shares - Dec. 5, 2017

PharmAthene director just picked up 33,315 shares - Nov. 30, 2017

PharmAthene director just picked up 21,808 shares - Nov. 27, 2017

PharmAthene director just picked up 18,331 shares - Nov. 21, 2017

Major owner of PharmAthene just picked up 182,262 shares - Nov. 16, 2017

Major owner of PharmAthene just picked up 40,099 shares - Nov. 16, 2017

PharmAthene: Altimmune Announces Third Quarter 2017 Financial Results - Nov. 9, 2017

PharmAthene Just Filed Its Quarterly Report: 5. Net Loss Per Sh... - Nov. 9, 2017

Confidential treatment order - Oct. 26, 2017

Paradigm Venture Partners, L.P. just provided an update on activist position in PharmAthene - Oct. 19, 2017

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. BlackRock Fund Advisors 1,714,857 N/A Sept. 30, 2016
2. Potomac Capital Management, Inc. 591,134 0.7 Sept. 30, 2015
3. GRUBER & MCBAINE CAPITAL MANAGEMENT LLC 572,950 N/A March 31, 2015
4. BlackRock Institutional Trust Company, N.A. 485,324 N/A Dec. 31, 2016
5. MORGAN STANLEY 234,175 N/A Dec. 31, 2016
6. BlackRock Investment Management, LLC 233,794 N/A Dec. 31, 2016
7. BlackRock Advisors LLC 36,673 N/A Sept. 30, 2016
8. BlackRock Inc. 3,427 N/A Sept. 30, 2016
9. MetLife Securities, Inc 100 N/A Dec. 31, 2016
10. Kurt Wheeler 0 N/A March 24, 2016

Altimunne (ALT)

140
 


Feedback